223 related articles for article (PubMed ID: 31089794)
41. A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study.
Petzer AL; Sperr WR; Buxhofer-Ausch V; Sliwa T; Schmidt S; Greil R; Wölfler A; Pichler P; Dormann C; Burgstaller S; Tinchon C; Lang A; Goebel F; Uthman S; Muenchmeier N; Valent P
Wien Klin Wochenschr; 2020 Aug; 132(15-16):415-422. PubMed ID: 32533444
[TBL] [Abstract][Full Text] [Related]
42. [Comorbidity profile and its impact on reported outcome in Chinese patients with chronic myeloid leukemia in chronic phase receiving tyrosine kinase-inhibitor therapy].
Yu L; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):533-539. PubMed ID: 30122010
[No Abstract] [Full Text] [Related]
43. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
Jiang Q; Wang HB; Yu L; Gale RP
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
[TBL] [Abstract][Full Text] [Related]
44. Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.
Khoury HJ; Bixby DL
Leuk Lymphoma; 2015 Mar; 56(3):568-76. PubMed ID: 24884315
[TBL] [Abstract][Full Text] [Related]
45. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
Jiang Q; Yu L; Gale RP
J Cancer Res Clin Oncol; 2018 Apr; 144(4):735-741. PubMed ID: 29380058
[TBL] [Abstract][Full Text] [Related]
46. Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in patients with chronic myeloid leukemia.
Janssen L; Hopman MTE; Swaans GJA; Allard NAE; Boss M; Lobeek D; Gotthardt M; Schirris TJJ; Blijlevens NMA; Timmers S
Am J Physiol Endocrinol Metab; 2023 Mar; 324(3):E209-E216. PubMed ID: 36696600
[TBL] [Abstract][Full Text] [Related]
47. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
Iino M; Yamamoto T; Sakamoto Y
Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
[TBL] [Abstract][Full Text] [Related]
48. [Clinical analysis of chronic myeloid leukemia patients complicated with chronic kidney impairment during treatment with tyrosine kinase inhibitors].
Ando Y; Hangaishi A; Saika M; Chizuka A; Kida M; Usuki K
Rinsho Ketsueki; 2016 Mar; 57(3):340-5. PubMed ID: 27076247
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
Tokuhira M; Kimura Y; Sugimoto K; Nakazato T; Ishikawa M; Fujioka I; Takaku T; Iriyama N; Sato E; Fujita H; Hatta Y; Komatsu N; Asou N; Kizaki M; Kawaguchi T
Med Oncol; 2018 Feb; 35(3):38. PubMed ID: 29442179
[TBL] [Abstract][Full Text] [Related]
50. [Factors influencing severe cytopenia in chronic phase chronic myeloid leukemia patients receiving initial second generation tyrosine kinase inhibitors and its impact on treatment responses and outcomes].
Li ZY; Qin YZ; Lai YY; Shi HX; Hou Y; Zhang XS; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):295-301. PubMed ID: 37356998
[No Abstract] [Full Text] [Related]
51. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia.
Kenzik KM; Bhatia R; Williams GR; Bhatia S
Cancer; 2019 Aug; 125(15):2570-2578. PubMed ID: 30973642
[TBL] [Abstract][Full Text] [Related]
52. How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA).
Breccia M; Olimpieri PP; Olimpieri O; Pane F; Iurlo A; Foggi P; Cirilli A; Colatrella A; Cuomo M; Gozzo L; Summa V; Corradini P; Russo P;
Cancer Med; 2020 Jun; 9(12):4160-4165. PubMed ID: 32319737
[TBL] [Abstract][Full Text] [Related]
53. Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary.
Batar P; Alizadeh H; Rokszin G; Abonyi-Toth Z; Demeter J
Pathol Oncol Res; 2024; 30():1611497. PubMed ID: 38444749
[No Abstract] [Full Text] [Related]
54. [Fertility and disease outcomes in patients with chronic myeloid leukemia].
Dou XL; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):980-985. PubMed ID: 32023726
[No Abstract] [Full Text] [Related]
55. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
[TBL] [Abstract][Full Text] [Related]
56. Long-Term Efficacy of High-Dose Imatinib in Hispanic Patients Without Access to Second-Generation Tyrosine Kinase Inhibitors Treated in LATAM Centers.
Cantu-Rodriguez OG; Osorno-Rodriguez KL; Dorsey-Trevino EG; Gutierrez-Aguirre CH; Jaime-Perez JC; Gomez-Villarreal JP; Rios-Rodelo MR; Gonzalez-Cantu GA; Contreras-Arce A; Colunga-Pedraza PR; Gomez-De Leon A; Mancias-Guerra MDC; Tarin-Arzaga LDC; Gomez-Almaguer D
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):e386-e392. PubMed ID: 37625952
[TBL] [Abstract][Full Text] [Related]
57. Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician's perspective.
Pushpam D; Bakhshi S
Daru; 2020 Jun; 28(1):371-385. PubMed ID: 31900888
[TBL] [Abstract][Full Text] [Related]
58. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes.
Sasaki K; Jabbour EJ; Ravandi F; Konopleva M; Borthakur G; Wierda WG; Daver N; Takahashi K; Naqvi K; DiNardo C; Montalban-Bravo G; Kanagal-Shamanna R; Issa G; Jain P; Skinner J; Rios MB; Pierce S; Soltysiak KA; Sato J; Garcia-Manero G; Cortes JE
Am J Hematol; 2021 Feb; 96(2):241-250. PubMed ID: 33180322
[TBL] [Abstract][Full Text] [Related]
59. The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia.
Minson AG; Cummins K; Fox L; Costello B; Yeung D; Cleary R; Forsyth C; Tatarczuch M; Burbury K; Motorna O; Shortt J; Fleming S; McQuillan A; Schwarer A; Harrup R; Holmes A; Ratnasingam S; Chan KL; Hsu WH; Ashraf A; Putt F; Grigg A
Blood Adv; 2019 Apr; 3(7):1084-1091. PubMed ID: 30944100
[TBL] [Abstract][Full Text] [Related]
60. Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention.
Caocci G; Mulas O; Bonifacio M; Abruzzese E; Galimberti S; Orlandi EM; Iurlo A; Annunziata M; Luciano L; Castagnetti F; Gozzini A; Stagno F; Binotto G; Pregno P; Albano F; Martino B; Fozza C; Scaffidi L; Trawinska MM; Baratè C; Elena C; Cattaneo D; Scalzulli E; La Nasa G; Foà R; Breccia M
Int J Cardiol; 2019 Aug; 288():124-127. PubMed ID: 31029498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
